Ulcerative colitis (UC) is a chronic and progressive inflammatory disorder that affects the
colon. The advent of advanced therapies such as biologic agents and small molecules has …

Simple Summary Patients with inflammatory bowel disease (IBD) are at an increased risk of
developing colorectal cancer (CRC), mainly because of chronic intestinal inflammation …

Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits
IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and …

IL23 is a recognized cytokine involved in the pathogenesis of inflammatory bowel diseases
(IBD) 1. The first IL23-targeting agent that became available for clinical use in IBD was …

Pediatric Crohn's disease commonly presents with moderate-to-severe intestinal
inflammation with a greater risk of complications if remission is not achieved. Anti-tumor …

Advances in science have led to the development of multiple biologics and small molecules
for the treatment of inflammatory bowel diseases (IBD). This growth in advanced medical …

Background Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and
ulcerative colitis (UC), continues to challenge treatment paradigms. Advancements in …

Risankizumab is a humanized monoclonal antibody that inhibits the p19 subunit of IL-23
cytokine. Recently it has been approved for the treatment of patients with moderate-to …

Background & Aims The aim of this study was to assess the long-term effectiveness and
safety of risankizumab maintenance treatment in a large real-world cohort of patients with …

Background As real-world data on risankizumab in patients with moderate to severe Crohn's
disease (CD) are scarce, we evaluated its effectiveness and safety in multirefractory Belgian …